EP0733644A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Glucagon-like insulinotropic complexes, compositions and methods
Assignee: Eli Lilly and Co
•
Filing: 1995-05-23
•
Granted: —
•
Expires: 2015-05-23
Abstract
Abstract The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
Inventors
- 👤 John Allison Galloway
- 👤 James Arthur Hoffmann
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 15:30
CPC Classifications
C; C07; C07K; C07K17/00; C07K17/14; C07K14/00; C07K14/435; C07K14/575; C07K14/605; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/62; A61P; A61P3/00; A61P3/08; A61P3/10; A61P43/00; A61K38/00; Y; Y10; Y10S; Y10S977/00; Y10S977/70; Y10S977/773; Y10S977/902; Y10S977/904; Y10S977/915
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
147 words
A GLP-1 molecule complex consisting of a divalent metal cation associated with and capable of co-precipitating with a compound of the formula: R 1 -X-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Y-Gly-Gln-Ala-Ala-Lys-Z-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-R 2 wherein: R 1 is selected from the group consisting of L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, alpha-fluoromethyl-histidine, and alpha-methyl-histidine; X is selected from the group consisting of Ala, Gly, Val, Thr, Ile, and alpha-methyl-Ala; Y is selected from the group consisting of Glu, Gln, Ala, Thr, Ser, and Gly; Z is selected from the group consisting of Glu, Gln, Ala, Thr, Ser, and Gly; R 2 is selected from the group consisting of NH 2 , and Gly-OH; providing that the compound has an isoelectric point in the range from about 6.0 to about 9.0 and further providing that when R 1 is His, X is Ala, Y is Glu, and Z is Glu, R 2 must be NH 2 .
Claim 2
Dependent Claim
12 words
A complex of Claim 1 wherein said divalent metal cation is zinc.
Claim 3
Dependent Claim
18 words
A complex of Claim 2 wherein R 1 is chosen from the group consisting of His and desamino-histidine.
Claim 4
Dependent Claim
18 words
A complex of Claim 2 wherein X is chosen from the group consisting of Ala, Gly, and Val.
Claim 5
Dependent Claim
17 words
A complex of Claim 2 wherein Y is chosen from the group consisting of Glu and Gln.
Claim 6
Dependent Claim
17 words
A complex of Claim 2 wherein Z is chosen from the group consisting of Glu and Gln.
Claim 7
Dependent Claim
24 words
A complex of Claim 2 wherein R 1 is His, X is Val, Y is Glu, Z is Glu, and R 2 is Gly-OH.
Claim 8
Dependent Claim
24 words
A complex of Claim 2 wherein R 1 is His, X is Gly, Y is Gln, Z is Glu, and R 2 is Gly-OH.
Claim 9
Dependent Claim
39 words
A pharmaceutical formulation which comprises as an active ingredient, a complex, or a pharmaceutically acceptable salt thereof, as claimed in any one of Claims 1 to 8 associated with one or more pharmaceutically acceptable carriers, diluents, or excipients therefor.
Claim 10
Dependent Claim
25 words
A GLP-1 molecule complex, or a pharmaceutically acceptable salt thereof, as claimed in any one of Claims 1 to 8, for use in treating diabetes.
Claim 11
Dependent Claim
27 words
A process for preparing a GLP-1 molecule complex as claimed in any one of Claims 1-8, which comprises mixing a GLP-1 molecule with a divalent metal cation.
References Cited (Backward Citations)
WO1987006941A1
Cited
EP0587255A1
Cited
WO1991011457A1
Cited
WO1993025579A1
Cited
EP0619322A2
Cited
WO1995005848A1
Cited
EP0658568A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.